Tag: Bystander Effect
Unlocking the Potential of Antibody-drug Conjugates
One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He...
Following Positive Results of Phase III TULIP Trial: FDA Accepts Byondis’...
The U.S. Food & Drug Administration (FDA) has accepted Byondis' submission of a Biologics License Application (BLA) for trastuzumab duocarmazine (previously known as...
HER2, Trastuzumab and the Development of Novel Antibody-drug Conjugates
In the mid-1970s, scientists discovered that certain genes, when mutated, can cause cancer. Based on this observation they theorized that by targeting these oncogenes,...
Drug-detached Naked Antibody Impairs ADC Efficacy
Abstract
Armed with cytotoxic payloads, antibody-drug conjugate (ADC) becomes able to kill its naked-antibody-resistant tumor cell. When ADC circulates in the plasma, complete detachment of...
Data Confirms STRO-001 Eradicates B-Cell Hematologic Malignancies and Prolongs Survival
STRO-001, an antibody-drug conjugate or ADC targeting the CD74 cell surface protein in hematologic B-cell malignancies, being developed by Sutro Biopharma, has shown to...
